Rapid uptake and inhibition of viral propagation by extracellular OAS1

Journal of Interferon and Cytokine Research

Volumn 35, Issue 5, 2015, Pages 359-366

  Thavachelvam, Karthiga ^a   Gad, Hans Henrik ^a   Ibsen, Mikkel Søes ^a   Desprès, Philippe ^b   Hokland, Marianne ^a   Hartmann, Rune ^a   Kristiansen, Helle ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b INSTITUT PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; NUCLEOTIDYLTRANSFERASE; OLIGOADENYLATE SYNTHETASE 1; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; 2',5' OLIGOADENYLATE SYNTHETASE; ANTIVIRUS AGENT; PROTEIN BINDING; RECOMBINANT PROTEIN;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CHIKUNGUNYA VIRUS; CONTROLLED STUDY; ENCEPHALOMYOCARDITIS VIRUS; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; INTERNALIZATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; VIRUS REPLICATION; ANIMAL; CHLOROCEBUS AETHIOPS; DRUG EFFECTS; EXTRACELLULAR SPACE; GENETICS; HELA CELL LINE; METABOLISM; PHYSIOLOGY; PIG; PROTEIN TRANSPORT; VERO CELL LINE;

SUS;

2',5'-OLIGOADENYLATE SYNTHETASE; ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; ENCEPHALOMYOCARDITIS VIRUS; EXTRACELLULAR SPACE; HELA CELLS; HEPARIN; HUMANS; PROTEIN BINDING; PROTEIN TRANSPORT; RECOMBINANT PROTEINS; SWINE; VERO CELLS; VIRUS REPLICATION;

EID: 84928946992     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0140     Document Type: Article

References (24)

1. Ablasser A, Schmid-Burgk JL, Hemmerling I, Horvath GL, Schmidt T, Latz E, Hornung V. 2013. Cell intrinsic immunity spreads to bystander cells via the intercellular transfer of cGAMP. Nature 503(7477):530-534.
2. Barth H, Schafer C, Adah MI, Zhang F, Linhardt RJ, Toyoda H, Kinoshita-Toyoda A, Toida T, Van Kuppevelt TH, Depla E, Von Weizsacker F, Blum HE, Baumert TF. 2003. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem 278(42): 41003-41012.
3. Carocci M, Bakkali-Kassimi L. 2012. The encephalomyocar-ditis virus. Virulence 3(4):351-367.
4. Donovan J, Dufner M, Korennykh A. 2013. Structural basis for cytosolic double-stranded RNA surveillance by human oli-goadenylate synthetase 1. Proc Natl Acad Sci U S A 110(5): 1652-1657.
5. Hartmann R, Justesen J, Sarkar SN, Sen GC, Yee VC. 2003. Crystal structure of the 2¢-specific and double-stranded RNA-activated interferon-induced antiviral protein 2¢-5¢-oligoadenylate synthetase. Mol Cell 12(5):1173-1185.
6. Henrik Gad H, Paulous S, Belarbi E, Diancourt L, Drosten C, Kummerer BM, Plate AE, Caro V, Despres P. 2012. The E2-E166K substitution restores Chikungunya virus growth in OAS3 expressing cells by acting on viral entry. Virology 434(1):27-37.
7. Hogle JM. 2002. Poliovirus cell entry: common structural themes in viral cell entry pathways. Annu Rev Microbiol 56: 677-702.
8. Ibrahim J, Griffin P, Coombe DR, Rider CC, James W. 1999. Cell-surface heparan sulfate facilitates human immunodeficiency virus type 1 entry into some cell lines but not primary lymphocytes. Virus Res 60(2):159-169.
9. Kotenko SV. 2011. IFN-lambdas. Curr Opin Immunol 23(5): 583-590.
10. Kristiansen H, Gad HH, Eskildsen-Larsen S, Despres P, Hartmann R. 2011. The oligoadenylate synthetase family: an ancient protein family with multiple antiviral activities. J Interferon Cytokine Res 31(1):41-47.
11. Kristiansen H, Scherer CA, McVean M, Iadonato SP, Vends S, Thavachelvam K, Steffensen TB, Horan KA, Kuri T, Weber F, Paludan SR, Hartmann R. 2010. Extracellular 2¢-5¢ oli-goadenylate synthetase stimulates RNase L-independent antiviral activity: a novel mechanism of virus-induced innate immunity. J Virol 84(22):11898-11904.
12. Melchjorsen J, Kristiansen H, Christiansen R, Rintahaka J, Matikainen S, Paludan SR, Hartmann R. 2009. Differential regulation of the OASL and OAS1 genes in response to viral infections. J Interferon Cytokine Res 29:199-207.
13. Mihm U, Ackermann O, Welsch C, Herrmann E, Hofmann WP, Grigorian N, Welker MW, Lengauer T, Zeuzem S, Sarrazin C. 2009. Clinical relevance of the 2¢-5¢-oligoadenylate synthetase/RNase L system for treatment response in chronic hepatitis C. J Hepatol 50(1):49-58.
14. Mulloy B, Forster MJ, Jones C, Davies DB. 1993. N.m.r. and molecular-modelling studies of the solution conformation of heparin. Biochem J 293 (Pt 3):849-858.
15. Pfaffl MW. 2001. A new mathematical model for relative quantification in real time RT-PCR. Nucleic Acid Res 29(9):e45.
16. Shindo M, Hamada K, Morikawa T, Harano Y, Nakajima T, Okuno T. 2008. In vivo interferon system assessed by 2¢-5¢ oligoadenylate synthetase activity in chronic hepatitis C virus patients treated with pegylated interferon and ribavirin. He-patol Res 38(12):1213-1220.
17. Silverman RH. 2007. Viral encounters with 2¢, 5¢-oligoadenylate synthetase and RNase L during the interferon antiviral response. J Virol 81(23):12720-12729.
18. Simon Davis DA, Parish CR. 2013. Heparan sulfate: a ubiquitous glycosaminoglycan with multiple roles in immunity. Front Immunol 4:470.
19. Spillmann D. 2001. Heparan sulfate: anchor for viral intruders? Biochimie 83(8):811-817.
20. Tiwari V, Clement C, Duncan MB, Chen J, Liu J, Shukla D. 2004. A role for 3-O-sulfated heparan sulfate in cell fusion induced by herpes simplex virus type 1. J Gen Virol 85(Pt 4): 805-809.
21. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. 2006. Double-stranded RNA is produced by positivestrand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol 80(10): 5059-5064.
22. Wu JM, Eslami B. 1983. Synthesis and function of (2¢-5¢)An: inhibition of (2¢-5¢)An synthetase by heparin and the use of heparin-agarose for partial purification of (2¢-5¢)An synthetase from rabbit reticulocyte lysates. Biochem Int 6(2):207-216.
23. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. 2007. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81(14):7749-7758.
24. Zhu W, Li J, Liang G. 2011. How does cellular heparan sulfate function in viral pathogenicity? Biomed Environ Sci 24(1): 81-87.